Regulation FD Disclosure

Business Context and Reporting Period

Company: Conexeu Sciences Inc. (Nasdaq: CNXU)
Filing Type: Form 8-K (Current Report)
Date: July 7, 2026
Event: Completion of the P.R.O.O.F (Performance and Regeneration Outcomes of Flowable Collagen) preclinical program for the CXU™ platform.

Key Financial Metrics

This filing is a Regulation FD disclosure regarding a scientific milestone and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.

Material Changes and Milestones

  • Preclinical Completion: Successfully completed a 12-month preclinical study demonstrating tissue restoration in both small-volume (facial/cheek) and large-volume (200cc-equivalent) models.
  • Performance Benchmarks: The CXU™ platform met key mechanical thresholds for injectability (flow through fine-gauge needles) and volumizing performance (maintaining shape and fullness).
  • Market Opportunity: Management highlights a tissue-restoration gap driven by the GLP-1 weight-loss drug market, projected to grow from $0.7 billion to $2.0 billion by 2030.

Guidance, Outlook, and Risks

  • Regulatory Pathway: The Company plans to submit a predicate-based 510(k) application for a wound care device in Q1 2027. This pathway targets a 90-day FDA review.
  • Strategic Outlook: Wound care clearance is intended to serve as the foundation for expanding into the medical aesthetics injectable market.
  • Intellectual Property: The platform is protected by a multi-jurisdictional patent estate spanning over 40 jurisdictions, including the U.S., EU, Japan, and Australia.
  • Risks and Contingencies: The study results do not represent commercial launch or regulatory clearance. Detailed quantitative findings are withheld pending peer-reviewed publication. Future success depends on FDA review and clearance.

Investor Verification Checklist

  • Verify the specific timeline for the Q1 2027 510(k) submission and potential delays.
  • Monitor the publication of peer-reviewed data to validate the 12-month histologic results.
  • Assess the Company's cash runway given the lack of revenue and the costs associated with regulatory submissions and manufacturing.
  • Confirm the status of patent protection in key markets, particularly Canada where protection is noted as pending.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.